Avid Bioservices Inc (CDMO)

[biopharm]

The Bird & Bird team advised Precision for Medicine on the due diligence, signing and closing of the transaction, including IP patent due diligence and regulatory advice regarding the life sciences aspects of the deal.

Stefan Münch (Corporate/M&A, Munich) led the transaction on the German law aspects, assisted by counsel Stephan Kübler and associates Michael Gassner and Benedikt Weiss (both Corporate/M&A, Munich), partner Ralph Panzer and associate Julia Gottinger (both Employment, Munich), counsel Gerrit Wiedow (Employment, Hamburg), partners Michael Alt, Christopher Maierhöfer and associate Marie-Theres Schmid (all Patents, Munich), partner Markus Körner and counsel Thomas Urband (both Trademarks, Munich), partner Alexander Csaki and associate Clarissa Junge-Gierse (both Life Sciences/Regulatory, Munich) and partner Michael Jünemann (Finance, Frankfurt). Bird & Bird London partner Ali Ramadan and associate Hannah Fletcher (both Corporate/M&A, London) also assisted on the UK law issues. Legal in-house advisors were General Counsel John Mariano and Senior Counsel Rita Khoobchandani.

https://www.twobirds.com/en/news/press-releases/2017/germany/bird-and-bird-advises-precision-medicine-group-on-the-acquisition-of-epiontis

Peregrine Pharmaceuticals / Avid Bioservices as they worked with Epiontis and Precision For Medicine and has anyone been paying attention to legal parties here....and would Mark Ziebell not be required to be involved with this if PS Targeting Biomarker data was part of the reasons for why Epiontis was bought out ?

Has anyone emailed Epiontis / PFM / Avid Bioservices and Bird & Bird about concerns of what information was disclosed to some parties and not retail shareholders of PPHM, now CDMO